L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study.

ABSTRACT:

Background

L-carnitine is emerging as an item of interest for cardiovascular disease (CVD) prevention and treatment, but controversy exists. To examine the effectiveness and safety of L-carnitine, we assessed how genetically different levels of L-carnitine are associated with CVD risk and its risk factors. Given higher CVD incidence and L-carnitine in men, we also examined sex-specific associations.

Methods

We used Mendelian randomization to obtain unconfounded estimates. Specifically, we used genetic variants to predict L-carnitine, and obtained their associations with coronary artery disease (CAD), ischemic stroke, heart failure, and atrial fibrillation, as well as CVD risk factors (type 2 diabetes, glucose, HbA1c, insulin, lipid profile, blood pressure and body mass index

SUBMITTER: Zhao JV 

PROVIDER: S-EPMC9434903 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature